@article{article, title  = {{Reasons for Patients (Pts) Discontinuing Study Treatment (Tx) in the Phase 3 Alsympca Trial of Radium-223 Dichloride (Ra-223) in Castration-Resistant Prostate Cancer (Crpc) with Bone Metastases (Mets)}},

 publisher = {{Elsevier BV}},

 url = {{}},

 year = {{2014}},

 month = {{9}},

 author = {{Logue J and Wedel S and Chodacki A and Sartor O and Nilsson S and Coleman RE and James N and Aksnes A and Wahba M and Parker C}},

 doi = {{10.1093/annonc/mdu336.18}},

 volume = {{25}},

 journal = {{Annals of Oncology}},

 pages = {{iv264-iv264}},

 note = {{Accessed on 2025/10/10}}}